Aqueous solid ointment

MYPI2025003903A0Undetermined Publication Date: 2024-07-26MIKASA SEIYAKU CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003903
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-01-26
Publication Date
2024-07-26

AI Technical Summary

Technical Problem

Water-based solid ointments containing fatty acid salts are prone to precipitation of fatty acid salts or crystals at low temperatures, leading to changes in efficacy and safety, especially when stored at pH levels higher than 9, which can be harmful to the skin.

Method used

A specific combination of fatty acid salts, including palmitate, stearate, and behenate, in a ratio of 35:5 to 55:5 to 28, along with a lower alcohol and sucrose fatty acid ester, is used to prevent precipitation at pH levels between 6 to 9, maintaining transparency and shape retention.

Benefits of technology

The formulation effectively prevents the precipitation of fatty acid salts or crystals, ensuring transparency and shape retention of the ointment at low temperatures, even at pH levels between 6 to 9, thus maintaining safety and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025003903_DRAWING_001
    Figure PI2025003903_DRAWING_001
Patent Text Reader

Abstract

Disclosed is an aqueous solid ointment including a fatty acid salt, a lower alcohol, a sucrose fatty acid ester, water, and an active component. The present invention can provide an aqueous solid ointment which is transparent and has shape retainability and in which crystals including the fatty acid salt, or in some cases crystals including the fatty acid salt and the active ingredient, do not precipitate during storage at a low temperature even at a pH value of 6-9, as a result of selecting a combination including a certain fatty acid salt for the aqueous solid ointment and setting the proportion of the fatty acid salt to a certain value.
Need to check novelty before this filing date? Find Prior Art

Description

Water-based solid ointment

[0001] The present invention relates to an aqueous solid ointment containing a fatty acid salt, a lower alcohol, a sucrose fatty acid ester, water and an active ingredient, the aqueous solid ointment containing a combination of the active ingredient and a specific fatty acid salt.

[0002] Solid ointments are filled into suitable containers, such as squeeze-type or dial-type airtight containers, and have many advantages, such as the ability to apply them to the affected area without soiling the hands, the ability to administer them to a limited area, and the convenience of portability. A variety of solid ointments have been proposed and brought to market.

[0003] Among solid ointments, aqueous solid ointments prepared using a volatile component such as a lower alcohol and a water-soluble solidifying component such as a fatty acid salt contain a volatile component, which reduces stickiness when applied to the skin compared to oil-based solid ointments. Furthermore, they also provide a highly refreshing feeling, resulting in an extremely pleasant feel when used. However, aqueous solid ointments using a fatty acid salt as a solidifying component can easily precipitate crystals containing the fatty acid salt or, in some cases, additional active ingredients when stored at low temperatures, which can result in changes in efficacy and safety. While JP 2018-052902 A discloses a technology capable of suppressing crystal precipitation of fatty acid salts even when aqueous solid ointments are stored at low temperatures, in order to prepare an aqueous solid ointment that has excellent transparency with a visually refreshing feeling and sufficient shape retention for application to affected areas, it was necessary to make the pH alkaline at a level higher than 9. Repeated use of alkaline aqueous solid ointments with a pH higher than 9 prepared in this manner may adversely affect the skin.

[0004] An object of the present invention is to provide an aqueous solid ointment which, even at a pH of 6 to 9, does not precipitate crystals containing a fatty acid salt or, in some cases, an active ingredient when stored at low temperatures, and which has transparency and shape retention.

[0005] As a result of extensive research aimed at solving the above-mentioned problems, the present inventors have discovered that, in an aqueous solid ointment containing a fatty acid salt, a lower alcohol, a sucrose fatty acid ester, water, and an active ingredient, by selecting a specific combination of fatty acid salts and adjusting the fatty acid salts to a specific ratio, an aqueous solid ointment can be obtained that is transparent and has shape-retaining properties and does not precipitate crystals of the fatty acid salt or, in some cases, the active ingredient even when stored at low temperatures, even at a pH of 6 to 9. This finding led to the completion of the present invention. That is, the present invention provides an invention having the following main features or aspects:

[0006] Aspect 1: An aqueous solid ointment comprising a fatty acid salt, a lower alcohol, a sucrose fatty acid ester, water, and an active ingredient, wherein the fatty acid salts include palmitate, stearate, and behenate, and the ratio of palmitate to stearate to behenate contained is within the range of 35-90:5-55:5-28, when the total weight of the palmitate, stearate, and behenate contained is taken as 100, and the aqueous solid ointment contains 3-8 wt% of the three types of fatty acid salts in total, calculated as fatty acids, 50-90 wt% of the lower alcohol, 0.1-2.5 wt% of the sucrose fatty acid ester, 1-20 wt% of water, and 0.1-10 wt% of the active ingredient, and has a pH of 6-9. Aspect 2: The aqueous solid ointment according to Aspect 1, wherein the active ingredient is an anti-inflammatory and analgesic ingredient.

[0007] Aspect 3: The aqueous solid ointment according to Aspect 2, wherein the anti-inflammatory and analgesic ingredient is at least one selected from diclofenac, loxoprofen, flurbiprofen, and salts thereof.

[0008] As described above, the present invention can provide an aqueous solid ointment that is transparent and has shape-retaining properties, and that does not precipitate crystals containing fatty acid salts or, in some cases, additional active ingredients even at a pH of 6 to 9 when stored at low temperatures.

[0009] FIG. 1 shows the weight ratios (in terms of fatty acids) of palmitate, stearate, and behenate contained in the aqueous solid ointments of Examples 1 to 7 and Comparative Examples 1 to 14 relative to the total weight of these fatty acid salts, calculated as fatty acids. FIG. 2 shows the weight ratios (in terms of fatty acids) of palmitate, stearate, and behenate contained in the aqueous solid ointments of Examples 8 to 13 and Comparative Examples 15 to 18 relative to the total weight of these fatty acid salts, calculated as fatty acids.

[0010] The aqueous solid ointment of the present invention will be described in detail below, but the present invention is not limited to the specific examples or technical terms used herein. The "pH" value of the aqueous solid ointment of the present invention is based on the measurement of the pH of a small amount of liquid on the solid surface of the aqueous solid ointment.

[0011] The intended pH of the aqueous solid ointment of the present invention is 6 to 9, or 7 to 9, or 6 to 8.5, or 7 to 8.5. An aqueous solid ointment that uses a fatty acid salt as a coagulation component may lose its shape retention if the pH is adjusted to below 6. Furthermore, if the pH is adjusted to above 9, repeated use may have an adverse effect on the skin.

[0012] The "crystal precipitation" in the aqueous solid ointment of the present invention is determined by visually inspecting the aqueous solid ointment after storage at a low temperature of 1°C to 15°C for 4 weeks, and if no crystals are observed in the aqueous solid ointment, it is defined as "no crystal precipitation."

[0013] The "transparency" of the aqueous solid ointment of the present invention is determined by measuring the light transmittance of an aqueous solid ointment filled in a cell with an optical path length of 10 mm at 15 to 25°C using a spectrophotometer at a wavelength of 660 nm, and is defined as transparency when the light transmittance is 30% or more. If the light transmittance is less than 30%, a visually refreshing feeling may not be obtained.

[0014] In the present invention, "shape retention" is determined by the total amount of energy (g·mm) required to penetrate 3.5 mm into the center of one base of an aqueous solid ointment at 24°C±2°C, cut into a cylindrical shape with a diameter of 37 mm or more and a height of 20 mm to 40 mm, in a direction perpendicular to the base, with a 7 mm diameter stainless steel spherical probe at a speed of 0.07 mm / sec. Shape retention is defined as a total energy of 900 g·mm or more. If the total energy is less than 900 g·mm, it may be difficult to maintain sufficient shape retention for application to the affected area. The aqueous solid ointment of the present invention contains three fatty acid salts as essential ingredients: palmitate, stearate, and behenate.

[0015] As the palmitate, sodium palmitate can be used alone or in combination with other palmitates. Examples of other palmitates include potassium palmitate, monoethanolamine palmitate, diethanolamine palmitate, and triethanolamine palmitate.

[0016] Similarly, the stearates may be sodium stearate alone or in combination with other stearates, such as potassium stearate, monoethanolamine stearate, diethanolamine stearate, and triethanolamine stearate.

[0017] Similarly, the behenate may be sodium behenate alone or in combination with other behenates. Examples of other behenates include potassium behenate, monoethanolamine behenate, diethanolamine behenate, and triethanolamine behenate.

[0018] The ratios of palmitate, stearate and behenate contained in the aqueous solid ointment of the present invention, calculated as the total parts by weight of the corresponding fatty acids, to 100, are within the ranges of 35-90:5-55:5-28, 40-90:5-50:5-25, 35-80:10-55:10-28, or 40-80:10-50:10-25, respectively.

[0019] The three types of fatty acid salts are contained in a total amount of 3 to 8% by weight, 3 to 6% by weight, 3.5 to 7% by weight, or 3.5 to 6% by weight in terms of fatty acids based on the total weight of the aqueous solid ointment.

[0020] In addition to the above three types of fatty acid salts, the aqueous solid ointment may contain other fatty acid salts within the scope of not impairing the effects of the present invention.The other fatty acid salts contained therein are generally derived from one or more types of oils and fats that are the raw materials for producing various fatty acid salts, and are not necessarily completely or easily removed when providing the above three types of fatty acid salts, such as caprylate, caprate, myristate, oleate, laurate, arachidate, erucate, linoleate, linolenate, lignocerate, etc.The fatty acid salt may be a fatty acid salt of the corresponding fatty acid that has been neutralized in advance, or a fatty acid salt formed by neutralizing a specific fatty acid and a base during the preparation process.

[0021] The ratio of the number of moles of the fatty acid salt to the number of moles of the corresponding fatty acid contained in the aqueous solid ointment of the present invention is within the range of 80-100:0-20, 90-100:0-10, or 95-100:0-5, where the sum of the number of moles of the fatty acid salt and the number of moles of the corresponding fatty acid is taken as 100.

[0022] The base used when neutralizing the fatty acid in the preparation process can be a base that forms a fatty acid sodium salt alone or a combination of a base that forms a fatty acid sodium salt and a base that forms other fatty acid salts. Examples of bases that form fatty acid sodium salts include sodium hydroxide, sodium carbonate, and sodium bicarbonate, which can be used alone or in combination of two or more. Examples of bases that form other fatty acid salts include potassium hydroxide, monoethanolamine, diethanolamine, and triethanolamine, which can be used alone or in combination of two or more.

[0023] Examples of the lower alcohols used in the present invention include lower alcohols having 6 or less carbon atoms, such as methanol, ethanol, propanol, isopropanol, butanol, pentanol, and hexanol, as well as modified versions of these alcohols, and these may be used alone or in combination. The lower alcohol content of the aqueous solid ointment is 50 to 90% by weight, 50 to 80% by weight, 55 to 85% by weight, or 55 to 80% by weight, based on the total weight of the aqueous solid ointment.

[0024] The sucrose fatty acid esters used in the present invention include sucrose fatty acid esters in which one or more fatty acids, such as caprylic acid, capric acid, stearic acid, palmitic acid, myristic acid, oleic acid, lauric acid, arachidic acid, behenic acid, erucic acid, linoleic acid, and linolenic acid, are ester-bonded to sucrose, and these sucrose fatty acid esters can be used alone or in combination of two or more. The sucrose fatty acid esters are contained in an amount of 0.1 to 2.5% by weight, 0.3 to 1% by weight, 0.1 to 0.7% by weight, or 0.3 to 0.7% by weight based on the total weight of the aqueous solid ointment.

[0025] Examples of water used in the present invention include purified water, sterilized water, natural water, tap water, water for injection, etc., which may be used alone or in combination of two or more. The water content of the aqueous solid ointment is 1 to 20% by weight, 5 to 15% by weight, 1 to 10% by weight, or 5 to 10% by weight, based on the total weight of the aqueous solid ointment.

[0026] The active ingredient used in the present invention is not particularly limited as long as it is medically or pharmaceutically acceptable, but an active ingredient with a molecular weight of 500 or less that has excellent transdermal absorbability is preferred. Examples include local anesthetic ingredients such as lidocaine, procaine, tetracaine, and ethyl aminobenzoate; antihistamine ingredients such as diphenhydramine and chlorpheniramine maleate; and anti-inflammatory and analgesic ingredients such as loxoprofen, indomethacin, diclofenac, flurbiprofen, and salts thereof. These ingredients may be used alone or in combination. The active ingredient is contained in an amount of 0.1 to 10 wt. %, 0.5 to 5 wt. %, 0.1 to 3 wt. %, or 0.5 to 3 wt. % based on the total weight of the aqueous solid ointment. The active ingredient can be appropriately adjusted and formulated taking into consideration the properties, dosage, transdermal absorbability, and effective blood concentration of the active ingredient.

[0027] In addition to the above-mentioned components, the aqueous solid ointment of the present invention may contain various components acceptable for preparing pharmaceuticals, such as polyhydric alcohols, pH adjusters, higher alcohols, surfactants, active ingredient solubilizers, essential oils, moisturizers, antioxidants, active ingredient stabilizers, and transdermal absorption enhancers, within the scope that does not impair the effects of the present invention.

[0028] Examples of polyhydric alcohols include ethylene glycol, diethylene glycol, polyethylene glycol, 1,3-butylene glycol, propylene glycol, and dipropylene glycol, and these may be used alone or in combination of two or more.

[0029] Examples of pH adjusters include hydrochloric acid, acetic acid, sodium acetate, potassium acetate, tartaric acid, sodium tartrate, lactic acid, sodium lactate, malic acid, and sodium malate, and these can be used alone or in combination of two or more.

[0030] Examples of higher alcohols include oleyl alcohol, stearyl alcohol, cetanol, myristyl alcohol, and lauryl alcohol, and these may be used alone or in combination of two or more.

[0031] Examples of the surfactant include alkylaryl polyether alcohols, higher alcohol sulfates, self-emulsifying glycerin monostearate, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycol, propylene glycol fatty acid esters, polyglycerin fatty acid esters, monoglycerin fatty acid esters, lauromacrogol, sodium lauryl sulfate, quaternary ammonium salts, lecithin, and hydrogenated lecithin, and these surfactants may be used alone or in combination of two or more.

[0032] Examples of active ingredient solubilizers include diisopropyl adipate, diethyl sebacate, isopropyl palmitate, isopropyl myristate, medium-chain fatty acid triglycerides, cetyl myristate, myristyl myristate, castor oil, crotamiton, squalane, squalene, and propylene carbonate, and these may be used alone or in combination of two or more.

[0033] Examples of essential oils include dl-menthol, l-menthol, l-menthone, limonene, pinene, piperitone, terpinene, terpinolene, terpinol, carveol, d-camphor, etc., and these can be used alone or in combination of two or more.

[0034] Examples of moisturizing agents include urea, glycerin, sorbitol, acetylglucosamine, and hyaluronic acid, and these may be used alone or in combination of two or more.

[0035] Examples of antioxidants include tocopherols such as dl-α-tocopherol acetate, dl-α-tocopherol, and d-δ-tocopherol, dibutylhydroxyanisole, dibutylhydroxytoluene, propyl gallate, L-ascorbic acid, and sodium ascorbate, and these can be used alone or in combination of two or more.

[0036] Examples of the active ingredient stabilizer include sodium hydrogen sulfite, sodium hydrogen phosphate, and sodium edetate, and these may be used alone or in combination of two or more.

[0037] Examples of the transdermal absorption enhancer include polyhydric alcohols such as ethylene glycol, 1,3-butylene glycol, propylene glycol, and glycerin; esters such as diisopropyl adipate, isopropyl myristate, ethyl acetate, cetyl lactate, and glycerin monooleate; surfactants such as sucrose oleate and sucrose laurate; essential oils such as dl-menthol, l-menthol, limonene, and peppermint oil; pyrrolidones such as N-methyl-2-pyrrolidone and pyrrolidonecarboxylic acid; α-hydroxy compounds such as lactic acid and glycolic acid; and aliphatic alcohols such as stearyl alcohol, myristyl alcohol, lauryl alcohol, and 2-ethyl-1,3-hexanediol, which may be used alone or in combination of two or more.

[0038] The aqueous solid ointment of the present invention can be prepared by a conventional method known in the art or a new method to be developed in the future.A typical preparation method is to add fatty acid salt or fatty acid and base, lower alcohol, sucrose fatty acid ester, water, active ingredient, polyhydric alcohol, pH adjuster, higher alcohol, surfactant, active ingredient solubilizer, essential oil, moisturizer, antioxidant, active ingredient stabilizer, transdermal absorption enhancer, etc. into a dissolving tank, and stir under heating and reflux until homogeneous.This is then filled into a container, cooled to room temperature, and solidified, thereby preparing the ointment.The container can be an airtight container, a push-out type, or a dial-out type container.

[0039] The present invention will be explained in more detail below with reference to specific examples, but the present invention is not limited to these.

[0040] Example 1: Each component was weighed based on the formulation shown in Table 1 and prepared by Preparation Method 1 described below to obtain an aqueous solid ointment. The obtained aqueous solid ointment was subjected to evaluations of pH, crystal precipitation, transparency, and shape retention according to Test Examples 1 to 4 described below. An aqueous solid ointment was obtained that had a suitable pH, did not precipitate crystals when stored at low temperature, and had transparency and shape retention. The results are shown in Table 1.

[0041] (Preparation Method 1) The weighed components were placed in a dissolution tank and refluxed while heating to 85° C. until homogeneous. The mixture was then filled into a container suitable for carrying out Test Examples 1 to 4 described below, and cooled to room temperature to solidify, yielding an aqueous solid ointment.

[0042] (Test Example 1) pH Evaluation The pH of each of the aqueous solid ointments of Example 1 described above, Examples 2 to 20 described below, and Comparative Examples 1 to 24 was measured using a pH composite electrode (GST-5723S, manufactured by DKK-TOA Corporation), and a pH of 6 to 9 was evaluated as being suitable.

[0043] (Test Example 2) Evaluation of Crystal Precipitation The aqueous solid ointments of Example 1 described above, Examples 2 to 20 described below, and Comparative Examples 1 to 24 described below were filled into airtight containers and stored at 5°C for 4 weeks, and the presence or absence of crystal precipitation was visually confirmed and evaluated as follows. However, aqueous solid ointments that were not evaluated as having a suitable pH in Test Example 1 were not subjected to this test. ◯: No crystal precipitation ×: Crystal precipitation

[0044] (Test Example 3) Transparency Evaluation Aqueous solid ointments of Example 1 described above, and Examples 2 to 20 and Comparative Examples 1 to 24 described below, filled in polystyrene cells with an optical path length of 10 mm and kept at 15 to 25°C, were measured for light transmittance at a wavelength of 660 nm using a spectrophotometer (V-560 model, manufactured by JASCO Corporation), and ointments with a light transmittance of 30% or more were evaluated as having transparency. However, this test was not carried out on aqueous solid ointments that were evaluated as having crystal precipitation in Test Example 2.

[0045] (Test Example 4) Shape Retention Evaluation Aqueous solid ointments of Example 1 described above, Examples 2 to 20 described below, and Comparative Examples 1 to 24 were cut into cylindrical shapes with a diameter of 40 mm and a height of 20 to 40 mm and kept at 24°C ± 2°C. A texture analyzer (TA-XT plus, manufactured by Stable Micro Systems) was used to measure the total energy (g mm) required for a 7 mm diameter stainless steel spherical probe to penetrate 3.5 mm into the center of one of the bottom surfaces in a direction perpendicular to the bottom surface at a speed of 0.07 mm / sec. The measurement was carried out three times in total, and when the average value of the total energy was 900 g mm or more, the ointment was evaluated as having shape retention. However, this test was not carried out on aqueous solid ointments that were evaluated as having crystal precipitation in Test Example 2. Table 1: Table 2: The relationships between the data in Tables 1 and 2 above are shown in FIG.

[0046] (Examples 2 to 7) Each component was weighed based on the formulation shown in Table 1 and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation, crystal precipitation evaluation, transparency evaluation, and shape retention evaluation according to Test Examples 1 to 4, aqueous solid ointments were obtained that had an appropriate pH, did not precipitate crystals when stored at low temperature, and had transparency and shape retention. The evaluation results are also shown in Table 1, so please refer to them.

[0047] (Comparative Examples 1 to 4) Each component was weighed based on the formulation shown in Table 1 and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to evaluation of pH, crystal precipitation, transparency, and shape retention according to Test Examples 1 to 4, it was found that the pH was appropriate and no crystal precipitation occurred when stored at low temperature, but an aqueous solid ointment having transparency and shape retention was not obtained. The evaluation results are also shown in Table 1, so please refer to them.

[0048] (Comparative Examples 5 to 14) Each component was weighed based on the formulation shown in Table 2 and prepared by the above-mentioned Preparation Method 1 to obtain aqueous solid ointments. When the obtained aqueous solid ointments were subjected to pH evaluation and crystal precipitation evaluation according to Test Examples 1 and 2, it was found that although the pH was appropriate, no aqueous solid ointment was obtained that did not precipitate crystals when stored at low temperature. The evaluation results are also shown in Table 2, so please refer to them. Table 3: The relationships between the data in Table 3 above are shown in FIG.

[0049] (Examples 8 to 13) Each component was weighed based on the formulation shown in Table 3 and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation, crystal precipitation evaluation, transparency evaluation, and shape retention evaluation according to Test Examples 1 to 4, aqueous solid ointments were obtained that had an appropriate pH, were free from crystal precipitation when stored at low temperature, and had transparency and shape retention. The evaluation results are also shown in Table 3, so please refer to them.

[0050] (Comparative Examples 15 to 16) Each component was weighed based on the formulation shown in Table 3, and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation and crystal precipitation evaluation according to Test Examples 1 and 2, it was found that although the pH was appropriate, no aqueous solid ointment was obtained that did not precipitate crystals when stored at low temperature. The evaluation results are also shown in Table 3, so please refer to them.

[0051] (Comparative Examples 17 to 18) Each component was weighed based on the formulation shown in Table 3 and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation, crystal precipitation evaluation, transparency evaluation, and shape retention evaluation in accordance with Test Examples 1 to 4, it was found that the pH was appropriate and no crystal precipitation occurred when stored at low temperature, but an aqueous solid ointment with transparency and shape retention was not obtained. The evaluation results are also shown in Table 3, so please refer to them. Table 4:

[0052] (Comparative Example 19) Each component was weighed based on the formulation shown in Table 4, and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the pH of the obtained aqueous solid ointment was evaluated according to Test Example 1, no aqueous solid ointment with a suitable pH was obtained. The evaluation results are also shown in Table 4, so please refer to them.

[0053] (Comparative Examples 20 to 22) Each component was weighed based on the formulation shown in Table 4 and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation and crystal precipitation evaluation according to Test Examples 1 and 2, it was found that although the pH was appropriate, no aqueous solid ointment was obtained that did not precipitate crystals when stored at low temperature. The evaluation results are also shown in Table 4, so please refer to them. Table 5:

[0054] (Examples 14 to 20) Each component was weighed based on the formulation shown in Table 5 and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation, crystal precipitation evaluation, transparency evaluation, and shape retention evaluation according to Test Examples 1 to 4, aqueous solid ointments were obtained that had an appropriate pH, were free from crystal precipitation when stored at low temperature, and had transparency and shape retention. The evaluation results are also shown in Table 5, so please refer to them.

[0055] (Comparative Example 23) Each component was weighed based on the formulation shown in Table 5, and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. The obtained aqueous solid ointment was subjected to pH evaluation, crystal precipitation evaluation, transparency evaluation, and shape retention evaluation according to Test Examples 1 to 4. It was found that the pH was appropriate and no crystal precipitation occurred when stored at low temperature, but an aqueous solid ointment with transparency and shape retention was not obtained. The evaluation results are also shown in Table 5, so please refer to them.

[0056] (Comparative Example 24) Each component was weighed based on the formulation shown in Table 5, and prepared by the above-mentioned Preparation Method 1 to obtain an aqueous solid ointment. When the obtained aqueous solid ointment was subjected to pH evaluation, crystal precipitation evaluation, transparency evaluation, and shape retention evaluation according to Test Examples 1 to 4, it was found to have an appropriate pH, no crystal precipitation when stored at low temperature, and had shape retention, but a transparent aqueous solid ointment was not obtained. The evaluation results are also shown in Table 5, so please refer to them.

[0057] The present invention relates to an aqueous solid ointment that is transparent and has shape-retaining properties and does not produce crystals containing fatty acid salts or, in some cases, additional active ingredients even when stored at low temperatures, even at a pH of 6 to 9, and is therefore industrially applicable.

Claims

1. An aqueous solid ointment comprising a fatty acid salt, a lower alcohol, a sucrose fatty acid ester, water and an active ingredient, wherein the fatty acid salt comprises a palmitate, a stearate and a behenate, and the ratio of the palmitate, the stearate and the behenate contained therein is within the range of 35-90:5-55:5-28 when the total weight parts converted into the corresponding fatty acids is taken as 100, the aqueous solid ointment comprises 3-8% by weight of the three types of fatty acid salts in total, calculated as fatty acids, 50-90% by weight of the lower alcohol, 0.1-2.5% by weight of the sucrose fatty acid ester, 1-20% by weight of water and 0.1-10% by weight of the active ingredient, and has a pH of 6-9.

2. The aqueous solid ointment according to claim 1, wherein the active ingredient is an anti-inflammatory and analgesic ingredient.

3. The aqueous solid ointment according to claim 2, wherein the anti-inflammatory and analgesic ingredient is at least one selected from the group consisting of diclofenac, loxoprofen, flurbiprofen and salts thereof.